Companies Dominating the Epidural Abscess Treatment Landscape
- Alembic Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- Sandoz Inc.
- Sun Pharmaceutical Industries Limited
- Novartis AG
- Sanofi-aventis Groupe
- Abbott Laboratories
- Merck & Co., Inc.
- Pfizer Inc.
- Siemens Healthcare GmbH
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of epidural abscess treatment is evaluated at USD 52.87 billion.
The epidural abscess treatment market size was valued at USD 45.6 billion in 2024 and is set to exceed USD 150.14 billion by 2037, expanding at over 9.6% CAGR during the forecast period i.e., between 2025-2037. The surge in head surgeries, rising cases of otitis media, and increasing ratio of traumatic brain injury will boost the market growth.
North America industry is predicted to dominate majority revenue share of 38% by 2037, propelled by high healthcare expenditure, followed by rising frequency of epidural abscess cases in the region.
The major players in the market are Alembic Limited, Eli Lilly and Company, Sandoz Inc., Sun Pharmaceutical Industries Limited, Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Pfizer Inc., Siemens Healthcare GmbH
